Physician

Matthew Alan Taub, M.D.

According to 2025 Medicare claims, Matthew Taub, M.D. (NPI: 1396784807) practices hematology/oncology in the Fort Lauderdale-Pompano Beach-Sunrise, FL market, with the plurality of this provider's patient population coming from Broward, FL. This provider's primary affiliated billing organization is MATTHEW TAUB MD PA (NPI: 1992007496; TIN: 020673693) and primary practice location at 33021-3420. Taub is affiliated with the American Choice Healthcare, LLC (ACO ID: D0086), participating under the REACH model.

Taub's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 559 traditional Medicare patients, billed 100,072 HCPCS/CPT codes, and received $1,030,214 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,200 prescription claims across 267 beneficiaries totaling $10,832,193 in drug costs, led by Lenalidomide (Lenalidomide). 2020 DME data shows 34 claims. Open Payments data shows 259 records totaling $5,199. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $437,823 to $1,030,214. Similarly, Part D prescription costs have moved sharply higher in recent years, from $1,388,549 to $10,832,193. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	158	32,274	$437,823
2016	195	51,374	$674,451
2017	190	34,407	$372,887
2018	256	36,700	$494,731
2019	254	49,169	$637,657
2020	266	52,730	$755,430
2021	287	56,341	$1,074,676
2022	318	81,593	$1,177,980
2023	397	68,026	$1,187,702
2024	559	100,072	$1,030,214

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	218	857	$1,388,549
2016	237	1,073	$2,211,768
2017	223	952	$2,628,910
2018	216	924	$3,280,844
2019	228	965	$4,208,356
2020	242	1,151	$6,520,385
2021	285	1,349	$8,977,829
2022	251	1,351	$11,336,545
2023	275	1,353	$10,495,818
2024	267	1,200	$10,832,193

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	34	$1,963
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	221	705	$107
99221	Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes	246	294	$72
99231	Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes	221	1,844	$43
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	154	491	$8
36415	Insertion of needle into vein for collection of blood sample	159	423	$5

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lenalidomide	Lenalidomide	125	3,444	$1,870,056
Pomalyst	Pomalidomide	36	1,008	$784,902
Imbruvica	Ibrutinib	40	1,168	$680,804
Xtandi	Enzalutamide	47	1,410	$667,998
Revlimid	Lenalidomide	39	1,015	$660,509

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	259	$5,199	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Matthew Alan Taub, M.D.?

Tedicare shows public-source Medicare data for Matthew Alan Taub, M.D. (NPI 1396784807), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Matthew Alan Taub, M.D. have ACO affiliation data?

Matthew Alan Taub, M.D. is shown with ACO affiliation data for American Choice Healthcare, LLC (REACH, ACO ID D0086).

What billing organization is linked to Matthew Alan Taub, M.D.?

Matthew Alan Taub, M.D. is linked to MATTHEW TAUB MD PA (billing NPI 1992007496) in the available physician profile data.

Does Matthew Alan Taub, M.D. have Open Payments data?

Matthew Alan Taub, M.D. has 259 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.